These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 23599364)

  • 21. Tamoxifen or raloxifene for breast cancer chemoprevention: a tale of two choices--point.
    Jordan VC
    Cancer Epidemiol Biomarkers Prev; 2007 Nov; 16(11):2207-9. PubMed ID: 18006908
    [No Abstract]   [Full Text] [Related]  

  • 22. Raloxifene prevails in STAR trial, may face easier road to acceptance than previous drugs.
    Vastag B
    J Natl Cancer Inst; 2006 Jun; 98(11):733-5. PubMed ID: 16757696
    [No Abstract]   [Full Text] [Related]  

  • 23. Breast cancer risk reduction: what do we know and where should we go?
    Prout MN
    Medscape Womens Health; 2000; 5(5):E4. PubMed ID: 11113777
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis.
    Grann VR; Jacobson JS; Whang W; Hershman D; Heitjan DF; Antman KH; Neugut AI
    Cancer J Sci Am; 2000; 6(1):13-20. PubMed ID: 10696733
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.
    Lee WL; Chao HT; Cheng MH; Wang PH
    Maturitas; 2008 Jun; 60(2):92-107. PubMed ID: 18534794
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of tamoxifen in the long-term treatment and prevention of breast cancer.
    Jordan VC
    Oncology (Williston Park); 1988 Sep; 2(9):19-28. PubMed ID: 3079292
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Endocrine therapy for early breast cancer.
    Hussain SA; Williams S; Stevens A; Rea DW
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):877-88. PubMed ID: 15485321
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen.
    Goss PE; Ingle JN; Pater JL; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Cameron DA; Palmer MJ; Tu D
    J Clin Oncol; 2008 Apr; 26(12):1948-55. PubMed ID: 18332475
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Breast cancer risks and prevention: implications of the Breast Cancer Prevention Trial results.
    Crowell EB; Jubelirer SJ
    W V Med J; 2000; 96(6):598-601. PubMed ID: 11194088
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk.
    Lippman ME; Cummings SR; Disch DP; Mershon JL; Dowsett SA; Cauley JA; Martino S
    Clin Cancer Res; 2006 Sep; 12(17):5242-7. PubMed ID: 16951244
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent results from clinical trials using SERMs to reduce the risk of breast cancer.
    Vogel VG
    Ann N Y Acad Sci; 2006 Nov; 1089():127-42. PubMed ID: 17261762
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).
    Beattie MS; Costantino JP; Cummings SR; Wickerham DL; Vogel VG; Dowsett M; Folkerd EJ; Willett WC; Wolmark N; Hankinson SE
    J Natl Cancer Inst; 2006 Jan; 98(2):110-5. PubMed ID: 16418513
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemoprevention of breast cancer.
    O'Regan RM
    Cancer Treat Res; 2000; 103():183-207. PubMed ID: 10948447
    [No Abstract]   [Full Text] [Related]  

  • 34. To switch or not to switch: should the study of tamoxifen and raloxifene (STAR) trial alter our decision?
    Wang PH; Chao HT
    Taiwan J Obstet Gynecol; 2008 Sep; 47(3):372-4. PubMed ID: 18936014
    [No Abstract]   [Full Text] [Related]  

  • 35. Poor risk assessment limits breast cancer survival.
    Reinke T
    Manag Care; 2013 Sep; 22(9):6-7. PubMed ID: 24164004
    [No Abstract]   [Full Text] [Related]  

  • 36. Prophylaxis of hereditary breast cancer.
    de Groot JS; van Diest PJ; Derksen PWB
    Aging (Albany NY); 2017 Dec; 9(12):2453-2454. PubMed ID: 29227964
    [No Abstract]   [Full Text] [Related]  

  • 37. Protocols and IRB approval for post-menopausal pregnancies.
    Mueller MJ
    Fertil Steril; 1997 Dec; 68(6):1153; author reply 1154-5. PubMed ID: 9418718
    [No Abstract]   [Full Text] [Related]  

  • 38. Protocols and IRB approval for post-menopausal pregnancies.
    Check JH; Chern RA
    Fertil Steril; 1997 Dec; 68(6):1153-4. PubMed ID: 9418719
    [No Abstract]   [Full Text] [Related]  

  • 39. Breast cancer drugs should be offered to healthy but high risk women, US panel concludes.
    McCarthy M
    BMJ; 2013 Apr; 346():f2499. PubMed ID: 23599364
    [No Abstract]   [Full Text] [Related]  

  • 40. The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women.
    Bevers TB
    J Natl Compr Canc Netw; 2007 Sep; 5(8):719-24. PubMed ID: 17927929
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.